Sign in to continue:

Sunday, February 8th, 2026

KPJ Healthcare (KPJ MK) – on track to achieve a 20% year-on-year growth in medical tourism revenue for 2024, with the Malaysia Healthcare Travel Council targeting a revenue of RM2.4 billion for the year.

KPJ Healthcare (KPJ MK) – Update

Share Price: RM2.07 | Target Price: RM1.90 | Rating: HOLD

Company Overview

  • KPJ Healthcare is Malaysia’s largest private hospital operator.
  • The company is undergoing a transformation programme aimed at strengthening its market position, enhancing operational efficiencies, and boosting profitability.

Key Highlights

  1. Transformation Programme:
    • KPJ’s medium-term growth is underpinned by both brownfield capacity expansions and its five-year transformation plan.
    • This transformation includes pillars such as branding, culture activation, and digitalisation.
    • A key feature of this digital-first approach is the “One Patient, One Record” concept, consolidating medical information across its hospital network into a single, comprehensive patient record accessible throughout its facilities. This initiative is further supported by its mobile app.
  2. Capacity Building:
    • KPJ aims to increase capacity to 5,000 beds by 2028 from the current 3,733 beds.
    • KPJ is effectively managing asset optimisation through hospital gestation and asset divestment, improving performance across its portfolio.
  3. Medical Tourism Growth:
    • KPJ is strategically focusing on medical tourism, targeting secondary markets such as Bangladesh, India, MENA, and China.
    • The company is on track to achieve a 20% year-on-year growth in medical tourism revenue for 2024, with the Malaysia Healthcare Travel Council targeting a revenue of RM2.4 billion for the year.
  4. Financial Performance:
    • Most of KPJ’s loss-making hospitals are expected to break even by year-end, except for the Miri Hospital, which continues to face challenges in attracting consultants.
    • KPJ is expecting continued financial improvement, with earnings supported by its expansion efforts and medical tourism growth.

Valuation & Recommendation:

  • KPJ’s target price remains at RM1.90, with a HOLD rating maintained. While the company’s transformation efforts and growth strategies are promising, most of these outcomes have already been priced into the stock.

Key Risks:

  • Potential delays in hospital openings or regulatory changes.
  • The challenge of managing higher operating costs while maintaining profitability.

Conclusion:

  • KPJ Healthcare’s transformation programme is proceeding well, with promising growth in capacity and medical tourism. However, the positive outcomes from these initiatives are largely priced into the current share price, resulting in a HOLD recommendation at a target price of RM1.90.Thank you

400 Capitol Sold by MUST for US$117 Million to Strengthen Financial Position

Date of Report: September 30, 2024Broker Name: CGS International Securities Divestment of 400 Capitol by MUSTMUST has confirmed the sale of its property, 400 Capitol, for a total price of US$117 million. This transaction...

VISEN Pharmaceuticals’ HK$672 Million IPO: Pioneering Endocrine Therapies in Hong Kong’s Biotech Boom

​Visen Pharmaceuticals, a biopharmaceutical company specializing in endocrinology treatments in China, is set to list on the Hong Kong Stock Exchange under the ticker 02561.HK. The IPO is scheduled for March 21, 2025, aiming...

China Tourism Group Duty Free (1880 HK) Stock: Technical Buy Signal as Prices Bottom Out – July 2025 Hong Kong Retail Research Update

Broker: CGS International Date of Report: July 22, 2025 China Tourism Group Duty Free and Trip.com: Technical Buy Signals, Market Trends, and Trade Setups for 2025 Market Recap: Corporate America, Tariff Risks, and Earnings...